Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 729 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Tislelizumab August 4, 2023 Trial Examines Value of Lymph Node Surgery in Advanced Ovarian Cancer March 27, 2019 Liquid Biopsy Detects Brain Cancer and Early-Stage Kidney Cancer July 23, 2020 Hiding in plain sight: How we can use immune cells to... February 9, 2023 Load more HOT NEWS ctDNA-Guided Treatment Influence on Survival in Advanced NSCLC Surprise! Financial Assistance To Help With Your Medical Bills May Be... EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab A real Eureka moment for translation
